Can Valeant keep its debt-fueled M&A binge going strong enough? That's the question

Serial dealmaker Valeant ($VRX) seems to have bounced back since its failed bid for Allergan ($AGN) in November. The Canadian pharma has since inked two deals and is rumored to have another one in the works. But its heavy debt load has some questioning whether it can deliver on its goal of becoming one of the world's top 5 drugmakers by 2016. More from FiercePharma

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.